-

Bruker Introduces Vutara™ VXL Best-in-Class Super-Resolution Microscope and Spatial Biology Analysis Capabilities

Accessible 3D Single-Molecule Localization Microscopy for Studying Subcellular Organelles and Spatial Multiomics

MADISON, Wisc.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the release of the Vutara VXL Super-Resolution Fluorescence Microscope for nanoscale biological imaging. The new system opens an affordable and easy-to-use path for both core facilities and individual investigators to enter the world of super-resolution imaging by incorporating Bruker’s industry-leading single-molecule localization (SML) technology in a streamlined system with compact footprint.

Vutara VXL serves as a biological microscopy workstation for research on DNA, RNA and proteins, from macromolecular complexes and super-structures, to chromatin structure and chromosomal substructures, to studying functional relationships in genomes and in various subcellular organelles. This novel system also supports advanced spatial biology research in extracellular matrix structures, extracellular vesicles (EV), virology, neuroscience, and live-cell imaging. When combined with Bruker’s unique microscope fluidics unit, Vutara VXL enables multiplexed imaging for targeted, sub-micrometer multiomics in genomics, transcriptomics, and proteomics research. The Vutara VXL software already supports leading-edge methods, such as OligoSTORM, Optical Reconstruction of Chromatin Architecture (ORCA), and DNA PAINT labeling methodologies.

“I am thrilled about the release of Vutara VXL, as this instrument is fundamental in making SML microscopy more accessible to the scientific community, and to the spatial 3D genomics research community in particular,” said Jennifer E. Phillips-Cremins, Ph.D., Associate Professor of Biotechnology and Genetics at the University of Pennsylvania. “Witnessing first-hand Bruker’s software and hardware development to enhance the spatial genomics capabilities that are required for my research bears testament to both their dedication and the functionality and versatility of the Vutara platform.”

“We believe that enabling 3D single-molecule localization microscopy in the hands of more researchers will further advance a better understanding of cellular biology at the nano level, particularly in the emerging field of spatial omics imaging,” added Xiaomei Li, Ph.D., Vice President and General Manager of Bruker’s Fluorescence Microscopy business. “Combined with its large field of view and ability to perform optical nanoscopy, Vutara VXL delivers multimodal capabilities and high-throughput data acquisition to enable a wider range of studies for spatially resolved genomics and transcriptomics.”

About Vutara VXL

Based on the Vutara super-resolution platform’s proprietary biplane technology, proven industry-leading capabilities with fully integrated fluidics with unlimited multiplexing potential, and powerful analytical software, the new Vutara VXL facilitates scientific research from experiment initiation and data collection through analysis to publication. The system enables researchers to obtain intrinsic 3D super-resolution data and achieve 20 nm localization precision in XY, 50 nm in Z for organic dyes, and even finer with DNA PAINT probes. A proprietary emission path allows the system to achieve low background fluorescence, even in thick samples, routinely imaging large Z volumes in tissue slices up to 30 µm in thickness at arbitrary distances from the coverslip. With the SRX software package and its Quantitative Localization Microscopy analysis suite, Vutara VXL facilitates the entire imaging process from acquisition and localization, and provides in-depth visual and quantitative information from biological samples in a single, seamless workflow. Utilizing real-time localization analysis and data visualization, multi-location recording capabilities, and scripting functions for automated data analysis, completion of an entire workflow cycle can be accomplished in a matter of minutes, providing a significant enhancement to work throughput. As a multi-modality workstation for single-molecule localization microscopy as well as conventional diffraction-limited widefield imaging, Vutara VXL is an ideal platform for bioinformatics, such as looking at the spatial distribution of the transcriptome in conjunction with high-resolution genomic or proteomic imaging.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investors:
Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Stephen Hopkins
Content Marketing Manager
Bruker Nano Surfaces and Metrology Division
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Bruker Introduces Vutara™ VXL Best-in-Class Super-Resolution Microscope and Spatial Biology Analysis Capabilities
Release Versions

Contacts

Investors:
Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Stephen Hopkins
Content Marketing Manager
Bruker Nano Surfaces and Metrology Division
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

More News From Bruker Corporation

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit...

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus...
Back to Newsroom